Compare GSK plc (GSK) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Palantir Technologies Inc — how do they compare? GSK plc trades at $46.61 (market cap $91.88B), while Palantir Technologies Inc trades at $205.87 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 5.2× GSK plc's market cap, and GSK plc pays a 3.9% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Palantir Technologies Inc for 78 Days on average.
| GSK | PLTR | |
|---|---|---|
Market Cap | $91.88B | $477.68B |
Volume | 7,730,529 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $61.18 | $207.18 |
52-Week Low | $43.24 | $107.27 |
Typical Hold Time | 93 Days | 78 Days |
Enterprise Value | $111.88B | $468.48B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Palantir (PLTR) trades at $205.71, up 6.01% with strong bullish momentum. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025 and net income margin expanding to 36.3%. Technical indicators signal bullish sentiment with the price approaching resistance at $206. Recent partnership with Armada for sovereign AI infrastructure and consistent earnings beats highlight the company's growth trajectory.
Palantir presents compelling growth prospects driven by AI platform adoption, though premium valuations (P/E 169.9, P/S 83.02) warrant caution. Analyst consensus remains positive with 54% buy ratings and $191.69 price target. Key risks include valuation sensitivity and competitive pressures in the AI software space. The company's strong cash flow generation and expanding commercial customer base support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
